Importance The I-SPY2.2 trial tests personalized treatment strategies to improve outcomes while reducing exposure to standard chemotherapy in patients with high-risk early breast cancer (EBC). Objective To evaluate the efficacy and safety of trastuzumab-deruxtecan (T-DXd), an antibody drug conjugate targeting low ERBB2...
C. O'Sullivan, K. Kalinsky, C. Yau et al.· JAMA Oncology· 0 citations
PURPOSE
Thin-cut formalin-fixed paraffin-embedded (FFPE) tumor sections on glass slides represent a large, underused biorepository for precision oncology, but their long-term room temperature storage raises concerns about nucleic acid integrity and analytical validity. We evaluated whether 20- to 30-year-old archival b...
Donald J. Johann, James B. Hicks, K. Albain et al.· JCO Precision Oncology· 0 citations
Background The benefit from adjuvant chemotherapy varies among patients with postmenopausal, node-positive, hormone receptor-positive breast cancer. Genomic assays identify patients likely to benefit from chemotherapy but are expensive and tissue consuming. AI-enabled biomarkers may provide scalable alternatives. We pe...
A. Thompson, A. Meisner, K. Albain et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.